                         SEQUENCE LISTING

<110>  PHOENIX BIOTECHNOLOGY, INC.
 
<120>  Method and Improved Neuroprotective Composition for Treating 
       Neurological Conditions

<130>  PBI-14-PCT

<140>  PCT/US18/49358
<141>  2018-10-02

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  forward primer against mouse gene GCLC

<400>  1
tggccactat ctgcccaatt                                                   20


<210>  2
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  reverse primer against mouse gene GCLC

<400>  2
gtctgacacg tagcctcggt aa                                                22


<210>  3
<211>  17
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  forward primer against mouse gene Nqo1 gene

<400>  3
gcccgcatgc agatcct                                                      17


<210>  4
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  forward primer against mouse gene Nqo1 gene

<400>  4
sggtctcctc ccagacggtt t                                                 21


<210>  5
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  forward primer against Mus musculus gene Srxn1

<400>  5
gcttcctctc gggagtcctt                                                   20


<210>  6
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  reverse primer against Mus musculus gene Srxn1

<400>  6
cagcaacagc gactacgaag taa                                               23


<210>  7
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  forward primer against Mus musculus gene Hmox1

<400>  7
cctcactggc aggaaatcat c                                                 21


<210>  8
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  reverse primer against Mus musculus gene Hmox1

<400>  8
cctcgtggag acgctttaca ta                                                22


